[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"renal-artery-fibromuscular-dysplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:renal-artery-fibromuscular-dysplasia":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100586296","european-multicentre-study-of-long-term-results-following-visceral-arteries-revascularization-the-e-visar-study-100586296",false,"NCT06913530","European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study","E-VisAR","Inclusion Criteria:\n\n* Patients presenting with atherosclerotic disease, aneurysms, or dissection;\n* Pathologies involving one or more visceral vessels (celiac, mesenteric, renal arteries, and their branches);\n* Patients receiving revascularization, both surgical and endovascular, in elective and urgent\u002Femergent settings;\n* For the retrospective cohort, patients who underwent revascularization up to 20 years from the study launch regardless of the follow-up time.\n\nExclusion Criteria:\n\n* Absence of follow-up imaging available and\u002For reported in follow-up medical reports;\n* For the retrospective cohort, a follow-up shorter than three years.","ALL","18 Years",{"count":19,"type":20},500,"ESTIMATED","OBSERVATIONAL","Visceral arteries pathologies are a broad-spectrum of conditions with an extremely low incidence, estimated at 9.2% and 6.2% per 100,000 inhabitants for chronic and acute mesenteric ischemia, respectively, and 0.01-0.2% for aneurysms. The literature regarding the topic is limited in number and fragmented, having multiple vessels involved along with rare conditions caused by different aetiologies. However, these diseases are of utmost importance considering that acute presentation is common and the treatment in urgent setting is challenging and still facing high mortality rates. There are still several grey areas regarding the treatment of these pathologies. The last decades showed an increasing utilization of an endovascular approach to treat visceral vessel diseases. On one hand, the early- and mid-term superiority of endovascular revascularization vs. open surgical repair has been demonstrated considering the reduction of morbidity and mortality, and length of stay. However, publications reporting long-term (\\> five years) are still lacking.\n\nThis study is a real-word, ambispective, multi-arm, multicenter study that aims to evaluate the long-term results of visceral vessel revascularization in different diseases, districts, and approaches. Patients will be divided according to the target vessel and index disease. For each subgroup, a comparison between endovascular and open repair will be performed.\n\nThe primary outcome is to compare endovascular and open approach in terms of survival, further divided into overall and disease-related mortality, during long term follow-up (\\> 5 years). Moreover, early and mid-term data should be considered to provide reliable results. This outcome will be stratified as well within each disease- specific arm.\n\nAt the study launch, data collection of patients who have undergone visceral vessels revascularization in the previous 20 years will begin. At the same time, all new cases of visceral vessel revascularization will be proposed for enrollment and follow-up in the prospective arm. The retrospective cohort will provide informative results regarding the long-term survival of these patients. This information will be used to adjust the sample size for the prospective cohort.",[24,25,26,27,28,29,30,31,32],"Visceral Artery Aneurysm","Mesenteric Artery Ischemia","Renal Artery Aneurysm","Renal Artery Stenosis","Renal Artery Stenosis Atherosclerotic","Renal Artery Fibromuscular Dysplasia","Chronic Mesenteric Ischemia","Visceral Artery Dissection","Mesenteric Artery Dissection","NOT_YET_RECRUITING","2025-03-30",{"date":36,"type":37},"2025-04-06","ACTUAL",{"date":39,"type":20},"2025-04-01",{"date":41,"type":20},"2030-06-01",{"name":43,"class":44},"Azienda Ospedaliero-Universitaria di Modena","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":53,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100467207","renal-artery-fibromuscular-dysplasia-registry-100467207","NCT05363748","Renal Artery Fibromuscular Dysplasia Registry","A Prospective Study of the Renal Artery Fibromuscular Dysplasia Registry in China","Inclusion Criteria:\n\n1. Informed consent;\n2. Patients diagnosed with renal artery fibromuscular dysplasia (FMD), i.e. at least one string-of-beads (multifocal FMD) or focal stenosis (focal FMD). The diagnosis needs to be confirmed by at least one of the following imaging modalities: CT-angiography, MR-angiography or catheter-based angiography;\n3. Patients with so-called \"atypical renal artery FMD\" or \"renal artery FMD-like presentation\", i.e. patients presenting with at least one dissection or 2 aneurysms \\\u003C 60-year-old, in the absence string-of-beads, focal stenosis or evidence of inherited arteriopathy;\n4. Patients with established renal artery FMD younger than 18 years, without evidence of underlying syndromes such as Williams syndrome, Alagille syndrome or type 1 Neurofibromatosis;\n\nExclusion Criteria:\n\n1\\. Not eligible for inclusion or in situations considered unqualified for the study by the investigator;",{"count":19,"type":20},"10 Years","1. Study name: A Prospective Study of the Renal artery fibromuscular dysplasia Registry in China\n2. Rationale: Fibromuscular dysplasia (FMD) is an idiopathic systemic noninflammatory arterial disease resulting in narrowing of medium-sized arteries. Renal arteries are most commonly involved vessels, although it can also affect arteries in other vascular territories. Renal artery FMD is the second frequent cause of renovascular hypertension , especially in adolescents. The pathogenesis of FMD is still not understood. There were little Asians in the United States and the European\u002FInternational FMD registry.\n3. Objective: 1) To describe the characteristics of renal artery FMD; 2) To identify environmental\u002F hormonal factors and exposures (for example smoking) associated with the onset and progression of renal artery FMD; 3)To identify baseline characteristics of the disease associated with an increased risk of complications such as dissections, aneurysms, stroke or myocardial infarction; 4) To provide evidence-based algorithms for the management and follow-up of patients with renal artery FMD; 5) To establish a comprehensive imaging resource including a wide range of presentations of renal artery FMD.\n4. Study design: Prospective, multi-center, observational study.\n5. Study population: renal artery fibromuscular dysplasia\n6. Data Collections: 1) Data on demographic characteristics, clinical characteristics, blood routine, biochemical and plasmic electrolytes and vascular imaging were collected using a questionnaire; 2) The diagnosis of renal artery FMD was based on the identification of focal or multifocal FMD lesions in at least one arterial bed by computed tomography angiography, magnetic resonance angiography and\u002For digital subtraction angiographies; 3) For the patients with renal artery FMD, screening was performed to assess most arteries and multivessel FMD would be collected; 4) All patients would be followed up.\n7. Treatment: Standardized diagnosis and treatment procedure as recommended in the International Consensus on the diagnosis and management of fibromuscular dysplasia.\n8. Follow up: 3, 6, 12 months after diagnosis and every year after enrolled.\n9. Sample size estimation: About 5 hundred.\n10. Timeline: Start of subjects' enrollment: Jan 2021; End of subjects enrollment: December 2026; End of study: December 2036.\n11. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.",[29],[29,57],"Hypertension","RECRUITING","2023-11-15",{"date":61,"type":37},"2023-11-18",{"date":63,"type":37},"2021-10-01",{"date":65,"type":20},"2036-12-31",{"name":67,"class":44},"Shanghai Jiao Tong University School of Medicine",1]